Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of pralsetinib in non-small cell lung cancer

HIGHLIGHTS

• who: Sanjay Popat from the Institute Georgetown University , Roche Products Ltd, Welwyn Garden City, UK. , Cytel, Inc, Waltham, MA, USA. , Global Access, F. Hoffmann-La Roche, Basel, Switzerland. have published the Article: Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS
• what: To fill this evidence gap, one of the two goals of this study was to investigate the relative effectiveness of pralsetinib by comparing outcomes for RET fusion-positive patients receiving first-line (1 L . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.